Advertisement
Screener

ALTIMMUNE, INC. (ALT) Graph

ALT Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $18.66M; Operating expenses $26.23M; Income tax (m).
  • 2026-03-31: Revenue (m); Research and development $16.19M; Operating expenses $24.24M; Income tax (m).
  • 2025-12-31: Revenue $26.00K*; Research and development $18.41M*; Operating expenses $28.92M*; Income tax $0.00*.
  • 2025-09-30: Revenue $5.00K; Research and development $14.96M; Operating expenses $20.86M; Income tax (m).

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$18.66M$26.23M(m)-$22.82M
2026-03-31(m)$16.19M$24.24M(m)-$22.56M
2025-12-31$26.00K*$18.41M*$28.92M*$0.00*-$27.36M*
2025-09-30$5.00K$14.96M$20.86M(m)-$19.01M
2025-06-30$5.00K$17.24M$22.93M(m)-$22.15M
2025-03-31$5.00K$15.83M$21.82M-$681.00K-$19.57M
2024-09-30$5.00K$19.80M$24.77M$0.00-$22.84M
2024-06-30$5.00K$21.16M$26.75M$0.00-$24.64M
2024-03-31$5.00K$21.49M$26.80M$0.00-$24.39M
2023-09-30$362.00K$18.39M$22.90M$0.00-$20.67M
2023-06-30$6.00K$13.25M$18.01M$0.00-$16.06M
2023-03-31$21.00K$17.25M$21.78M$0.00-$20.07M
2022-09-30$2.00K$20.26M$24.75M-$197.00K-$23.52M
2022-06-30$8.00K$15.99M$20.40M$0.00-$20.11M
2022-03-31$32.00K$15.10M$19.53M$0.00-$19.43M
2021-09-30$158.00K$29.21M$33.36M$0.00-$33.51M
2021-06-30$137.00K$13.27M$25.00M$0.00-$24.83M
2021-03-31$838.00K$11.88M$15.70M$0.00-$14.86M
2020-09-30$2.94M$17.04M$21.26M-$482.02K-$17.77M
2020-06-30$721.64K$16.59M$19.14M-$1.58M-$16.77M
2020-03-31$2.21M$7.19M$9.52M-$3.25M-$3.89M
2019-09-30$643.98K$8.73M$11.92M-$58.50K-$10.94M
2019-06-30$1.63M$2.95M$5.18M(m)-$3.39M
2019-03-31$2.96M$3.22M$5.28M(m)-$2.10M
2018-09-30$2.63M$4.73M$6.69M-$829.39K-$2.35M
2018-06-30$2.42M$4.92M$7.85M-$1.50M-$9.14M
2018-03-31$2.69M$5.75M$8.69M-$991.64K-$3.17M
2017-09-30$4.59M$5.91M$35.54M-$1.53M-$29.91M
2017-06-30$3.04M$5.25M$7.05M-$993.71K-$3.11M
2017-03-31$299.57K$2.79M$4.82M-$1.00M-$4.58M
2016-12-31(m)(m)(m)(m)$77.80M
2016-09-30$901.04K$2.40M$5.69M$15.44K-$4.80M
2016-06-30$745.97K$1.38M$2.35M$15.44K-$1.62M
2016-03-31(m)$1.03M$2.26M$15.44K-$1.23M
2015-12-31(m)(m)(m)(m)-$1.24M
2015-09-30(m)$1.13M$2.81M$15.44K-$1.32M
2015-06-30(m)$1.22M$3.11M$11.07K-$2.34M
2015-03-31(m)$1.61M$5.91M$19.80K$1.46M
2014-12-31(m)(m)(m)(m)-$2.63M
2014-09-30(m)$1.73M$4.96M$25.07K-$4.63M
2014-06-30(m)$2.37M$4.83M(m)-$439.12K
2014-03-31(m)$3.43M$6.14M(m)-$2.26M
2013-12-31(m)(m)(m)(m)-$4.42M
2013-09-30(m)$2.56M$6.69M(m)-$3.95M
2013-06-30(m)$3.40M$5.78M$11.21K-$1.24M
2013-03-31(m)$5.23M$7.57M$9.74K-$2.11M
2012-12-31(m)(m)(m)(m)-$1.27M
2012-09-30(m)$5.14M$8.49M$22.07K-$213.94K
2012-06-30(m)$4.92M$7.78M$16.13K-$756.54K
2012-03-31(m)$4.71M$7.74M$150.41K-$2.68M
2011-12-31(m)(m)(m)(m)$749.19K
2011-09-30(m)$4.88M$8.28M(m)-$33.50K
2011-06-30(m)$5.98M$9.51M(m)-$2.44M
2011-03-31(m)$5.82M$10.88M(m)-$2.08M
2010-09-30(m)$6.17M$9.61M(m)-$4.33M
2010-06-30(m)$5.94M$10.32M(m)-$6.39M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$34.85M$50.47M(m)-$45.39M
2025-06-30$10.00K$33.06M$44.75M-$681.00K-$41.72M
2024-06-30$10.00K$42.64M$53.55M$0.00-$49.03M
2023-06-30$27.00K$30.50M$39.79M$0.00-$36.13M
2022-06-30$40.00K$31.10M$39.93M$0.00-$39.54M
2021-06-30$975.00K$25.15M$40.70M$0.00-$39.69M
2020-06-30$2.93M$23.78M$28.66M-$4.82M-$20.65M
2019-06-30$4.58M$6.16M$10.46M(m)-$5.48M
2018-06-30$5.11M$10.67M$16.54M-$2.49M-$12.31M
2017-06-30$3.34M$8.04M$11.87M-$993.71K-$7.69M
2016-06-30$1.25M$2.44M$4.46M$30.87K-$3.23M
2015-06-30(m)$2.84M$9.02M$30.87K-$877.54K
2014-06-30(m)$5.80M$10.97M(m)-$2.70M
2013-06-30(m)$8.64M$13.34M$20.95K-$3.35M
2012-06-30(m)$9.62M$15.51M$166.54K-$3.44M
2011-06-30(m)$11.80M$20.39M(m)-$4.51M
2010-06-30(m)$10.89M$20.84M(m)-$14.34M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$15.00K$48.02M$65.61M-$681.00K-$60.73M
2024-09-30$15.00K$62.45M$78.32M$0.00-$71.88M
2023-09-30$389.00K$48.89M$62.70M$0.00-$56.81M
2022-09-30$42.00K$51.36M$64.69M-$197.00K-$63.05M
2021-09-30$1.13M$54.36M$74.06M$0.00-$73.20M
2020-09-30$5.87M$40.82M$49.92M-$5.31M-$38.42M
2019-09-30$5.23M$14.89M$22.38M-$58.50K-$16.42M
2018-09-30$7.74M$15.39M$23.23M-$3.32M-$14.66M
2017-09-30$7.93M$13.95M$47.41M-$2.53M-$37.59M
2016-09-30$2.15M$4.85M$10.15M$46.31K-$8.02M
2015-09-30(m)$3.96M$11.84M$46.31K-$2.20M
2014-09-30(m)$7.53M$15.93M$48.10K-$7.33M
2013-09-30(m)$11.19M$20.03M(m)-$7.29M
2012-09-30(m)$14.76M$24.00M$188.61K-$3.65M
2011-09-30(m)$16.69M$28.67M(m)-$4.55M
2010-09-30(m)$17.06M$30.45M(m)-$18.67M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$41.00K$66.43M$94.53M-$681.00K-$88.09M
2024-12-31$20.00K$82.23M$103.19M(m)-$95.06M
2023-12-31$426.00K$65.80M$96.36M(m)-$88.45M
2022-12-31-$68.00K$70.54M$87.67M-$197.00K-$84.71M
2021-12-31$4.41M$74.54M$101.32M(m)-$97.09M
2020-12-31$8.19M$49.77M$62.98M-$5.42M-$49.04M
2019-12-31$5.80M$17.77M$27.27M-$58.50K-$20.52M
2018-12-31$10.33M$18.46M$53.17M-$6.15M-$39.17M
2017-12-31$10.74M$18.41M$62.78M-$5.64M-$46.43M
2016-12-31$3.24M$7.22M$14.33M$0.00-$11.09M
2015-12-31(m)$5.13M$14.04M$61.75K-$3.44M
2014-12-31(m)$9.32M$20.38M$61.75K-$9.96M
2013-12-31(m)$15.29M$28.75M$61.75K-$11.72M
2012-12-31(m)$19.51M$31.44M$195.53K-$4.92M
2011-12-31$24.27M$21.22M$35.99M(m)-$3.80M
2010-12-31$20.99M$20.88M$44.55M(m)-$34.85M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Monopar Therapeutics (MNPR)United States$0.598B-34.82
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
CorMedix Inc. (CRMD)United States$0.605B3.25
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
Neurogene Inc. (NGNE)$0.625B-4.46
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Indaptus Therapeutics, Inc. (INDP)United States$0.537B